Mesothelioma in iron ore (taconite) miners

Lambert et al1 report on the relationship between exposure to elongate mineral particles (EMPs) and the incidence of mesothelioma among Minnesota iron ore miners. In a previous study, mesothelioma mortality was found to be increased among workers employed in the Minnesota mining industry.2 Based on 30 observed deaths, a standardised mortality ratio (SMR) of 2.77 with a 95% CI of 1.87 to 3.96 was found among the 31 067 workers most likely engaged in taconite mining and refining, as opposed to haematite mining. Taconite, but not haematite, mining and processing is known to entail exposure to non-asbestiform amphibole and non-amphibole EMPs (predominantly). These results appear to be in contrast to the view that non-asbestiform EMPs are associated with little or no carcinogenic risk.3 However, the results were in agreement with the observation of an increased incidence of mesothelioma in Northeastern Minnesota, which is what...
Source: Occupational and Environmental Medicine - Category: Occupational Health Authors: Tags: Commentary Source Type: research

Related Links:

In conclusion, BAP1 loss demonstrated by IHC is seen in more than half of MM cases but none of ATs. Thus, BAP1 IHC represents a potential adjunct for distinguishing MM from benign mesothelial proliferations including in particular “MM with bland adenomatoid-like pattern versus benign ATs” on biopsy material and early mesothelioma with limited invasion.
Source: Applied Immunohistochemistry and Molecular Morphology - Category: Chemistry Tags: Research Articles Source Type: research
Although mesothelioma is the consequence of a protracted immune response to asbestos fibers and characterized by a clear immune infiltrate, novel immunotherapy approaches show less convincing results as compared to those seen in melanoma and non-small cell lung cancer. The immune suppressive microenvironment in mesothelioma is likely contributing to this therapy resistance. Therefore, it is important to explore the characteristics of the tumor microenvironment for explanations for this recalcitrant behavior. This review describes the stromal, cytokine, metabolic, and cellular milieu of mesothelioma, and attempts to make co...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Abstract A 64 year old male heating engineer was investigated for a persistent cough and found to have epithelioid mesothelioma with pleural effusion, lung nodules and increased thoracic lymph nodes. He declined standard of care treatment following his own research and he was enrolled in a named patient programme of IMM-101. He was advised to correct his low vitamin D3 level and to start using anti-inflammatories such as aspirin, bromelain and low dose Naltrexone. At review one year later a CT scan showed no change and he continued on the regimen. Four years after the diagnosis a CT scan showed that there was a mo...
Source: Respiratory Care - Category: Respiratory Medicine Authors: Tags: Respir Med Case Rep Source Type: research
Less is usually better than more when it comes to aggressive surgery for pleural mesothelioma, according to the latest and most-extensive comparative study. Throughout the last 25 years, surgical patients typically fared better with the lung-sparing pleurectomy and decortication (P/D) than with the more radical extrapleural pneumonectomy (EPP). “We found that the P/D approach should be preferred when technically feasible,” Dr. Dimitrios Magouliotis of the General University Hospital of Larissa in Greece, told The Mesothelioma Center at “We believe now the P/D should be the first choice.&rdqu...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Soltermann Malignant pleural effusion (MPE) is a severe condition of advanced tumors without effective therapy. We used digitalized immunohistochemical and transcriptional approaches to investigate the prognostic influence of immune cells and expression variance of associated immunomodulatory molecules in MPE. Cytology tissue microarrays were constructed from MPE cell blocks of 155 patients with five tumor entities. Immune cells lineage markers were quantified by computational cytopathology on immunohistochemistry. mRNA expression analysis of nine lineage markers and 17 immunomodulators was performed by NanoString. I...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Thoracic surgeon Dr. Marcelo DaSilva came to Orlando, Florida, with a lofty goal. He wants to make Central Florida a destination for patients diagnosed with malignant pleural mesothelioma. DaSilva also has the tools to make that goal a reality, building a mesothelioma specialty program at AdventHealth Orlando. “We want to make this a nationally — and internationally — recognized program,” DaSilva told The Mesothelioma Center at “People who come to Orlando will not only see Disney World, but they will see excellence in health care. We can do that here.” DaSilva was named chi...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
This article highlights what the pathologist needs to know regarding the clinical and radiographic presentation of mesothelioma, histologic features including subtypes and variants, and recent advances in immunohistochemical markers and molecular testing.
Source: Surgical Pathology Clinics - Category: Pathology Authors: Source Type: research
This study aimed to report long-term outcomes for low-grade PMP and MM treated by laparoscopic approach.MethodsFrom a prospectively maintained CRS-HIPEC database, all patients who underwent laparoscopic CRS-HIPEC with curative intent were analyzed. Selection criteria for laparoscopic approach were low-grade PMP or MM, with pathological confirmation prior to CRS-HIPEC, ASA 2, age  
Source: Surgical Endoscopy - Category: Surgery Source Type: research
This article has reviewed the epigenetic mechanisms involved in miRNA expression in MM, focusing on their role as biomarkers of early diagnosis and therapeutic effects.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Condition:   Mesothelioma Malignant Advanced Interventions:   Drug: Durvalumab;   Drug: Cisplatin;   Drug: Pemetrexed;   Drug: Carboplatin Sponsors:   University of Sydney;   Australasian Lung Cancer Trials Group;   PrECOG, LLC.;   AstraZeneca Not yet recruiting
Source: - Category: Research Source Type: clinical trials
More News: Asbestosis | Cancer & Oncology | Environmental Health | Mesothelioma | Occupational Health | Study